文献速递胸部肿瘤消化系统肿瘤

含新型自消除基团的抗体-依沙替康偶联物克服结肠癌和肺癌耐药

Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.
PubMed 文献 · Cancer Discov · 2023-01-01

研究设计了一类使用新型自消除T基团实现依沙替康无痕偶联与释放的抗体药物偶联物(ADC),靶向HER2、HER3和TROP2,在低靶点表达、大体积及多药耐药肿瘤中克服对DXd/SN-38 ADC的内在或治疗耐药。该类ADC在患者来源异种移植和类器官模型中显示持久抗肿瘤活性,包括EGFR外显子19缺失/T790M/C797S三突变肺癌和BRAF/KRAS-TP53双突变结肠癌,并与PARP/ATR抑制剂及抗PD-1治疗产生协同作用。非人灵长类中高耐受性支持其扩展获益人群的潜力。

要点

  • 新型自消除T基团实现依沙替康无痕偶联与释放,依沙替康对多药耐药敏感性较低且效力更强
  • 靶向HER2、HER3、TROP2的T基团-依沙替康ADC在低靶点表达、大体积及MDR+肿瘤中克服DXd/SN-38 ADC耐药
  • 在EGFR三突变肺癌和BRAF/KRAS-TP53双突变结肠癌模型中显示持久抗肿瘤活性,并与PARP/ATR抑制剂及抗PD-1协同

核心结论

  • 将新型自消除基团与拓扑异构酶I抑制剂依沙替康作为载荷结合的ADC,在低靶点表达和对DXd/SN-38 ADC耐药的MDR+肿瘤中显示深度且持久的缓解,且不增加毒性。
  • 该新型ADC类有望使超出当前方案的更多患者人群获益。

研究设计与样本

  • 研究设计了使用新型自消除T基团实现依沙替康无痕偶联与释放的ADC类。
  • 在患者来源异种移植和类器官模型中评估抗肿瘤活性,并在非人灵长类中评估耐受性。

主要发现

  • 靶向HER2、HER3和TROP2的抗体-T基团-依沙替康偶联物在低靶点表达、大体积及MDR+肿瘤中克服等效DXd/SN-38 ADC的内在或治疗耐药。
  • T基团-依沙替康ADC在代表未满足临床需求的患者来源异种移植和类器官模型中显示持久抗肿瘤活性,包括EGFR外显子19缺失/T790M/C797S三突变肺癌和BRAF/KRAS-TP53双突变结肠癌。
  • T基团-依沙替康ADC与PARP/ATR抑制剂及抗PD-1治疗显示协同作用。
  • T基团-依沙替康ADC类在非人灵长类中高耐受性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Antibody-drug conjugates (ADC) using DNA topoisomerase I inhibitor DXd/SN-38 have transformed cancer treatment, yet more effective ADCs are needed for overcoming resistance. We have designed an ADC class using a novel self-immolative T moiety for traceless conjugation and release of exatecan, a more potent topoisomerase I inhibitor with less sensitivity to multidrug resistance (MDR). Characterized by enhanced therapeutic indices, higher stability, and improved intratumoral pharmacodynamic response, antibody-T moiety-exatecan conjugates targeting HER2, HER3, and TROP2 overcome the intrinsic or treatment resistance of equivalent DXd/SN-38 ADCs in low-target-expression, large, and MDR+ tumors. T moiety-exatecan ADCs display durable antitumor activity in patient-derived xenograft and organoid models representative of unmet clinical needs, including EGFR ex19del/T790M/C797S triple-mutation lung cancer and BRAF/KRAS-TP53 double-mutant colon cancer, and show synergy with PARP/ATR inhibitor and anti-PD-1 treatment. High tolerability of the T moiety-exatecan ADC class in nonhuman primates supports its potential to expand the responding patient population and tumor types beyond current ADCs. SIGNIFICANCE: ADCs combining a novel self-immolative moiety and topoisomerase I inhibitor exatecan as payload show deep and durable response in low-target-expressing and MDR+ tumors resistant to DXd/SN-38 ADCs without increasing toxicity. This new class of ADCs has the potential to benefit an additional patient population beyond current options. See related commentary by Gupta et al., p. 817. This article is highlighted in the In This Issue feature, p. 799.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Weng W, Meng T, Zhao Q, et al. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023. PMID: 36693125. doi:10.1158/2159-8290.CD-22-1368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。